The primary events of the hemostatic response include adhesion of platelets to exposed collagen in the damaged vessel wall, and the subsequent activation of the adhered platelets; thus facilitating the recruitment of more platelets to the damaged area. These platelets form a platelet plug that initially stops the bleeding. The second stage in the hemostatic plug formation is the coagulation process, initiated by exposed tissue factor on subendothelial cells in the vessel wall. Coagulation is driven through a complex enzymatic pathway that involves several zymogene-to-enzyme conversion steps which allows the reaction to undergo great intrinsic amplification.
The many steps are strictly regulated and counter-acted by specific inhibitors on the surface of- and released by the adjacent cells in the intact vessel wall. The final step in this cascade is the conversion of soluble fibrinogen into an insoluble fibrin network, i.e. coagulation. The coagulation process is accelerated by activated platelets and will ultimately form a stabilizing fibrin network that will secure the platelet plug until the vessel wall can be restored.
There are many components in the vascular system that have important roles to play in both hemostasis and thrombosis; endothelium, platelets, leukocytes, immune system and the plasma coagulation system, to name the most significant. Another very important factor not to be overlooked is the constant movement of the blood throughout the vasculature. In fact, the rate of blood flow and the resulting shear forces have proved to be a key regulator of hemostatic function via the platelet and leukocyte interaction with components in the vessel wall.
In the healthy human, all these components work in concert in an interlinked system to rapidly achieve hemostasis; i.e. to stop bleeding after vessel injury.
However, when components in the vasculature or blood are affected by a state of disease or other external factors, the delicate balance of the hemostatic system may be disturbed and lead to unwanted and potentially harmful thrombosis or bleeding.
Cardiovascular disease is the predominant cause of death in the developed countries; therefore, cardiovascular research is one of the most important areas within the medical field.
Main Areas of Research
Haemostasis in cardiovascular diseases
- Evaluation of biomarkers, for example coagulation factor XI, D-dimer, GDF-15 and transthyretin, for coronary atherosclerosis and cardiovascular disease in the Linköping cohort of SCAPIS (Swedish Cardio Pulmonary bioImage Study).
- Haemostasis effects in COVID-19.
Coagulation
- Control of anticoagulation with warfarin – evaluation of external quality assessment in Sweden.
- Interference of direct-acting oral anticoagulants (DOACs) on factor VIII and IX measurement methods.
- Development and evaluation of platelet function testing with flow cytometry.
Mechanisms of haemostasis
- How is propagation of coagulation accomplished and how is thrombus growth limited?
- How contributes platelet activation to coagulation?
- How do the human platelet thrombin receptors GPIb, PAR1, and PAR4 act in concert to facilitate cellular responses?
- How is activation of platelets counteracted and balanced?
